{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:25:42Z","timestamp":1781663142534,"version":"3.54.5"},"reference-count":67,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG CCG 134157"],"award-info":[{"award-number":["RSG CCG 134157"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F31CA236372"],"award-info":[{"award-number":["F31CA236372"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F31CA250366"],"award-info":[{"award-number":["F31CA250366"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R00CA194309"],"award-info":[{"award-number":["R00CA194309"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA240625"],"award-info":[{"award-number":["R37CA240625"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-18-1-0103"],"award-info":[{"award-number":["W81XWH-18-1-0103"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011597","name":"Penn State Hershey Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011597","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.heliyon.2020.e05097","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T08:30:08Z","timestamp":1601368208000},"page":"e05097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-055X","authenticated-orcid":false,"given":"Chi-Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-6666","authenticated-orcid":false,"given":"Raquel","family":"Buj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6506-9103","authenticated-orcid":false,"given":"Erika S.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5279-862X","authenticated-orcid":false,"given":"Kelly E.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-2325","authenticated-orcid":false,"given":"Katherine M.","family":"Aird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.heliyon.2020.e05097_bib1","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"9951","key":"10.1016\/j.heliyon.2020.e05097_bib2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2020.e05097_bib3","first-page":"1687","article-title":"Treatment for recurrent ovarian cancer-at first relapse","volume":"2010","author":"Ushijima","year":"2010","journal-title":"J.\u00a0Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e05097_bib4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ygyno.2017.10.003","article-title":"PARP inhibitors: clinical utility and possibilities of overcoming resistance","volume":"147","author":"Bitler","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.heliyon.2020.e05097_bib5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair (Amst)"},{"issue":"18","key":"10.1016\/j.heliyon.2020.e05097_bib6","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-17-3770","article-title":"A\u00a0functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients","volume":"24","author":"Tumiati","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.heliyon.2020.e05097_bib7","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.embor.7400210","article-title":"ATM and ataxia telangiectasia","volume":"5","author":"McKinnon","year":"2004","journal-title":"EMBO Rep."},{"key":"10.1016\/j.heliyon.2020.e05097_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-011811-132509","article-title":"ATM and the molecular pathogenesis of ataxia telangiectasia","volume":"7","author":"McKinnon","year":"2012","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e05097_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(00)80086-0","article-title":"Atm-deficient mice: a paradigm of ataxia telangiectasia","volume":"86","author":"Barlow","year":"1996","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.heliyon.2020.e05097_bib10","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/0008-5472.CAN-19-2255","article-title":"ATM paradoxically promotes oncogenic transformation via transcriptional reprogramming","volume":"80","author":"Liu","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2020.e05097_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbacli.2014.08.001","article-title":"ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers","volume":"2","author":"Abdel-Fatah","year":"2014","journal-title":"BBA Clin."},{"key":"10.1016\/j.heliyon.2020.e05097_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2020.e05097_bib13","doi-asserted-by":"crossref","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","article-title":"ATM in DNA repair in cancer","volume":"203","author":"Jin","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e05097_bib14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4161\/cc.11.6.19576","article-title":"Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control","volume":"11","author":"Golding","year":"2012","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.heliyon.2020.e05097_bib15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1535-7163.MCT-12-0707","article-title":"Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer","volume":"12","author":"Batey","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e05097_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2011.12.043","article-title":"Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling","volume":"319","author":"Fujimaki","year":"2012","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e05097_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","article-title":"Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically","volume":"19","author":"Riches","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e05097_bib18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.celrep.2015.04.014","article-title":"ATM couples replication stress and metabolic reprogramming during cellular senescence","volume":"11","author":"Aird","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2020.e05097_bib19","article-title":"ATM inhibition drives metabolic adaptation via induction of macropinocytosis","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.heliyon.2020.e05097_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3389\/fonc.2017.00291","article-title":"Ataxia-Telangiectasia mutated modulation of carbon metabolism in cancer","volume":"7","author":"Dahl","year":"2017","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e05097_bib21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0958-1669(99)00030-0","article-title":"Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions","volume":"10","author":"Michalik","year":"1999","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.heliyon.2020.e05097_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2020.e05097_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006796","article-title":"Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human","volume":"4","author":"Rakhshandehroo","year":"2009","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.heliyon.2020.e05097_bib24","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ncpcardio1278","article-title":"Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease","volume":"5","author":"Staels","year":"2008","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"10.1016\/j.heliyon.2020.e05097_bib25","doi-asserted-by":"crossref","first-page":"102737","DOI":"10.1155\/2008\/102737","article-title":"The role of PPARs in cancer","volume":"2008","author":"Tachibana","year":"2008","journal-title":"PPAR Res."},{"issue":"9","key":"10.1016\/j.heliyon.2020.e05097_bib26","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.7150\/jca.24488","article-title":"Anticancer properties of fenofibrate: a repurposing use","volume":"9","author":"Lian","year":"2018","journal-title":"J.\u00a0Cancer"},{"issue":"7353","key":"10.1016\/j.heliyon.2020.e05097_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research, N.","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.heliyon.2020.e05097_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.heliyon.2020.e05097_bib29","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e05097_bib30","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.xcrm.2020.100004","article-title":"Proteogenomic characterization of ovarian HGSC implicates mitotic kinases, replication stress in observed chromosomal instability","volume":"1","author":"McDermott","year":"2020","journal-title":"Cell Rep. Med."},{"issue":"24","key":"10.1016\/j.heliyon.2020.e05097_bib31","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.heliyon.2020.e05097_bib32","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.cellsig.2008.04.011","article-title":"ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells","volume":"20","author":"Halaby","year":"2008","journal-title":"Cell. Signal."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e05097_bib33","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2011-08-373639","article-title":"Mitochondrial dysfunction in ataxia-telangiectasia","volume":"119","author":"Valentin-Vega","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.heliyon.2020.e05097_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049513","article-title":"Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin","volume":"7","author":"Zakikhani","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.heliyon.2020.e05097_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2015.12.009","article-title":"ATM kinase: much more than a DNA damage responsive protein","volume":"39","author":"Guleria","year":"2016","journal-title":"DNA Repair (Amst)"},{"issue":"7391","key":"10.1016\/j.heliyon.2020.e05097_bib36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.heliyon.2020.e05097_bib37","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/cas.12899","article-title":"Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells","volume":"107","author":"Misumi","year":"2016","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.heliyon.2020.e05097_bib38","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","article-title":"Oxidative phosphorylation as an emerging target in cancer therapy","volume":"24","author":"Ashton","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2020.e05097_bib39","article-title":"Suppression of p16 alleviates the senescence-associated secretory phenotype","author":"Buj","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.heliyon.2020.e05097_bib40","doi-asserted-by":"crossref","DOI":"10.1158\/1541-7786.MCR-18-1233","article-title":"Targeting IDH1 as a pro-senescent therapy in high-grade serous ovarian cancer","author":"Dahl","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"8","key":"10.1016\/j.heliyon.2020.e05097_bib41","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.celrep.2019.07.084","article-title":"Suppression of p16 induces mTORC1-mediated nucleotide metabolic reprogramming","volume":"28","author":"Buj","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2020.e05097_bib42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1083\/jcb.201608026","article-title":"HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci","author":"Aird","year":"2016","journal-title":"J.\u00a0Cell Biol."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e05097_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4161\/cc.26953","article-title":"Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer","volume":"13","author":"Aird","year":"2014","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.heliyon.2020.e05097_bib44","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.celrep.2013.03.004","article-title":"Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence","volume":"3","author":"Aird","year":"2013","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.heliyon.2020.e05097_bib45","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1091\/mbc.e11-10-0884","article-title":"Lamin B1 loss is a senescence-associated biomarker","volume":"23","author":"Freund","year":"2012","journal-title":"Mol. Biol. Cell"},{"issue":"11","key":"10.1016\/j.heliyon.2020.e05097_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx059","article-title":"Drugging the cancers addicted to DNA repair","volume":"109","author":"Nickoloff","year":"2017","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.heliyon.2020.e05097_bib47","article-title":"Cellular senescence is a central response to cytotoxic chemotherapy in high-grade serous ovarian cancer","author":"Calvo","year":"2018","journal-title":"bioRxiv"},{"issue":"20","key":"10.1016\/j.heliyon.2020.e05097_bib48","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/jnci\/djq364","article-title":"Therapy-induced senescence in cancer","volume":"102","author":"Ewald","year":"2010","journal-title":"J\u00a0Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.heliyon.2020.e05097_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrc3057","article-title":"Pro-senescence therapy for cancer treatment","volume":"11","author":"Nardella","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"10.1016\/j.heliyon.2020.e05097_bib50","doi-asserted-by":"crossref","first-page":"14729","DOI":"10.18632\/oncotarget.4411","article-title":"ATM in senescence","volume":"6","author":"Aird","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.heliyon.2020.e05097_bib51","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/emboj.2010.330","article-title":"ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair","volume":"30","author":"Cosentino","year":"2011","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.heliyon.2020.e05097_bib52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.humpath.2008.09.019","article-title":"Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival","volume":"40","author":"Davidson","year":"2009","journal-title":"Hum. Pathol."},{"issue":"4","key":"10.1016\/j.heliyon.2020.e05097_bib53","first-page":"833","article-title":"Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer","volume":"18","author":"Shigeto","year":"2007","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.heliyon.2020.e05097_bib54","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1158\/1535-7163.MCT-06-0722","article-title":"Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer","volume":"6","author":"Yokoyama","year":"2007","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2020.e05097_bib55","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejphar.2017.05.008","article-title":"In vitro and in vivo pharmacology of NXT629, a novel and selective PPARalpha antagonist","volume":"809","author":"Stebbins","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2020.e05097_bib56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cell.2005.02.003","article-title":"Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors","volume":"120","author":"Campisi","year":"2005","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.heliyon.2020.e05097_bib57","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/1541-7786.MCR-16-0099","article-title":"Targeting RRM2 and mutant BRAF is a novel combinatorial strategy for melanoma","volume":"14","author":"Fatkhutdinov","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"8","key":"10.1016\/j.heliyon.2020.e05097_bib58","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/1541-7786.MCR-18-1233","article-title":"Targeting IDH1 as a prosenescent therapy in high-grade serous ovarian cancer","volume":"17","author":"Dahl","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"19","key":"10.1016\/j.heliyon.2020.e05097_bib59","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1158\/0008-5472.CAN-11-1341","article-title":"Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence","volume":"71","author":"Bitler","year":"2011","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.heliyon.2020.e05097_bib60","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"269","key":"10.1016\/j.heliyon.2020.e05097_bib61","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"8","key":"10.1016\/j.heliyon.2020.e05097_bib62","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.celrep.2019.07.084","article-title":"Suppression of p16 induces mTORC1-mediated nucleotide metabolic reprogramming","volume":"28","author":"Buj","year":"2019","journal-title":"Cell Rep."},{"issue":"43","key":"10.1016\/j.heliyon.2020.e05097_bib63","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7580","key":"10.1016\/j.heliyon.2020.e05097_bib64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature15736","article-title":"Pharmacogenomic agreement between two cancer cell line data sets","volume":"528","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2020.e05097_bib65","first-page":"13","article-title":"Detection of mycoplasma contaminations","volume":"290","author":"Uphoff","year":"2005","journal-title":"Methods Mol. Biol."},{"issue":"18","key":"10.1016\/j.heliyon.2020.e05097_bib66","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"20","key":"10.1016\/j.heliyon.2020.e05097_bib67","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1073\/pnas.92.20.9363","article-title":"A\u00a0biomarker that identifies senescent human cells in culture and in aging skin in vivo","volume":"92","author":"Dimri","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402031940X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402031940X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:47:00Z","timestamp":1769158020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402031940X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S240584402031940X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e05097","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.29.123919","asserted-by":"object"}]},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e05097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e05097"}}